Cost-Effectiveness of Incorporating [ <sup>89</sup> Zr]Zr-Girentuximab PET-CT for Characterizing Small Renal Masses
Using TLX250-CDx to characterize SRMs followed by confirmatory biopsy of negative cases helps avoid biopsy for nearly 60% of patients and treatment of over two-thirds of benign tumors, minimizes the risk of untreated malignancy (<1%), and is likely cost-effective compared with current conventional practices.
Authors
- M. Allaf
- Pratik Kanabur (ORCID: https://orcid.org/0000-0002-1102-5727)
- Zhuo T. Su (ORCID: https://orcid.org/0000-0003-3215-6192)
- Brian M. Shuch
- Austin Y. Ho
- Nirmish Singla
- Aboubacar Kaba
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Johns Hopkins Medicine (US)
- Virginia Commonwealth University Medical Center (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1097/ju.0000000000004912
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00